An­oth­er play­er drops out of the biosim­i­lars busi­ness as shake­out con­tin­ues

The shake­out on the hot­ly com­pet­i­tive biosim­i­lars front is con­tin­u­ing.

Just a few weeks af­ter Mer­ck KGaA made its ex­it from the field af­ter strik­ing a deal to sell off its port­fo­lio of bi­o­log­ic knock­offs to Fre­se­nius for €170 mil­lion up front, In­dia’s Cipla says it plans to ex­e­cute a re­treat from biosim­i­lars.

CEO Umang Vohra says he’s look­ing for part­ners to pick up on the biosim­i­lar pro­grams it has un­der­way, say­ing the field is get­ting too com­pet­i­tive to con­tin­ue to pump mon­ey in­to R&D.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.